News & Updates

Offspring born to mothers with Crohn’s disease (CD), but not ulcerative colitis, are at higher risk of infection, suggests a study. This association is partly mediated by adverse birth outcomes and antitumour necrosis factor α (anti-TNFα) agents.

Higher concentrations of infliximab postinduction results in favourable clinical outcomes in paediatric patients with Crohn’s disease (CD) both in the short and long term, reports a study.

Treatment with rifaximin appears to produce significant reductions in multiple, concurrent symptoms of irritable bowel syndrome (IBS) with diarrhoea, according to a study that uses a novel tri-symptom endpoint.

The use of the novel selective JAK-1 inhibitor upadacitinib appears to result in rapid symptom improvements in patients with difficult-to-treat ulcerative colitis or Crohn’s disease, including those who have prior exposure to tofacitinib, according to real-world data.